ArticleHaematologica2010
Efficacy and outcome of autologous transplantation in rare myelomas.
Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis.Transplantation and cellular therapy · 2026Article
- Immunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report.Journal of neurological surgery reports · 2024Article
- Amyloidosis: a case series and review of the literature.Journal of medical case reports · 2023Review
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.Blood advances · 2022Article
- A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.Journal of experimental & clinical cancer research : CR · 2022Article
- IgE multiple myeloma: detection and follow-up.Advances in laboratory medicine · 2022Article
- [Immunoglobulin M multiple myeloma: a six-case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Review
- "D" is for Dilemma.Cureus · 2019Article
- Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.BMC cancer · 2018Article
- N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.BMC cancer · 2017Article
- [Clinical characteristics analyses of 27 cases of immunoglobin D multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report.Oncology letters · 2016Article
- [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.International journal of hematology · 2014Article
- Serum Free Light Chain Only Myeloma with Cytoplasmic IgM.Case reports in hematology · 2014Article
- IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.Journal of experimental & clinical cancer research : CR · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 5 countries.
Funding
Abstract
backgroundAs rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their prognosis in the era of peripheral stem cell transplantation. DESIGN AND
methodsWe used the European Group for Blood and Marrow Transplantation Myeloma Database to compare the outcome following autologous transplantation of over 20,000 patients with common myelomas (IgG, IgA and light chain myeloma) with the outcome of patients with rare myelomas: 379 IgD, 13 IgE, 72 IgM and 976 non-secretory cases.
resultsThe study confirms the multiple adverse prognostic factors seen in IgD myeloma. Somewhat surprisingly, patients with IgD and non-secretory myeloma both had higher complete remission rates before and after transplantation than patients with common myelomas. However, while the overall survival of patients with non-secretory myeloma was similar to that of the patients with common myelomas, the survival of patients with IgD myeloma was significantly worse (although better than survival rates reported for non-transplanted patients); this was due to higher transplant-related mortality and relapse/progression rates. The post-transplantation survival of patients with IgE or IgM myeloma appears to be very poor.
conclusionsThis study provides data on the biological features of rare myelomas. The overall survival of patients with IgD, IgE or IgM myeloma is poor following autologous transplantation but substantially better than that reported for patients who were not transplanted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.